In Vitro and In Vivo Characterization of Neurally Modified Mesenchymal Stem Cells Induced by Epigenetic Modifiers and Neural Stem Cell Environment

被引:65
作者
Alexanian, Arshak R. [1 ]
Maiman, Dennis J. [1 ]
Kurpad, Shekar N. [1 ]
Gennarelli, Thomas A. [1 ]
机构
[1] Vet Adm Med Ctr, Dept Neurosurg, Neurosci Res Labs, Milwaukee, WI 53295 USA
关键词
D O I
10.1089/scd.2007.0212
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Mesenchymal stem cell (MSC)-mediated tissue regeneration is a promising strategy to treat several neurodegenerative diseases and traumatic injuries of the central nervous system. Bone marrow MSCs have great potential as therapeutic agents, since they are easy to isolate and expand and are capable of producing various cell types, including neural cells. Recently we developed a highly efficient methodology to produce neural stem-like and neural precursor-like cells from mice bone marrow-derived MSCs that eventually differentiate into neuronaland glial-like cells in vitro. The aim of this study is to further elucidate neural expression profile of neurally induced mesenchymal stem cells (NI-MSCs) and their ability to retain neural differentiation potential when grafted into the intact spinal cord of rats. To this end, we further characterized in vitro and in vivo properties of NI-MSCs by immunocytochemistry, Western blot, ELISA, and immunohistochemistry. Immunocytochemical data demonstrated that NI-MSCs express several mature neural markers such as B3T, GFAP MAP-2, NF-200, and NeuN, which were confirmed through Western blot. ELISA data showed that NI-MSCs release nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). In vivo studies demonstrated that grafted NI-MSCs survived after transplantation into intact spinal cord and produced cells that expressed neural markers. All these data suggest that neurally modified MSCs, induced by recently developed methodology, could be a potential source of cells to replace damaged neurons and glia in injured spinal cord, and/or to promote cell survival and axonal growth of host tissue.
引用
收藏
页码:1123 / 1130
页数:8
相关论文
共 55 条
[1]   Efficient differentiation and integration of lineage-restricted neural precursors in the traumatically injured adult cat spinal cord [J].
Alexanian, AR ;
Crowe, MJ ;
Kurpad, SN .
JOURNAL OF NEUROSCIENCE METHODS, 2006, 150 (01) :41-46
[2]   Neural stem cells induce bone-marrow-derived mesenchymal stem cells to generate neural stem-like cells via juxtacrine and paracrine interactions [J].
Alexanian, AR .
EXPERIMENTAL CELL RESEARCH, 2005, 310 (02) :383-391
[3]   Epigenetic modifiers promote efficient generation of neural-like cells from bone marrow-derived mesenchymal cells grown in neural environment [J].
Alexanian, Arshak R. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 100 (02) :362-371
[4]   Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats [J].
Ankeny, DP ;
McTigue, DM ;
Jakeman, LB .
EXPERIMENTAL NEUROLOGY, 2004, 190 (01) :17-31
[5]   Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray [J].
Bertani, N ;
Malatesta, P ;
Volpi, G ;
Sonego, P ;
Perris, R .
JOURNAL OF CELL SCIENCE, 2005, 118 (17) :3925-3936
[6]  
BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287
[7]   Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage [J].
Cao, QL ;
Zhang, YP ;
Howard, RM ;
Walters, WM ;
Tsoulfas, P ;
Whittemore, SR .
EXPERIMENTAL NEUROLOGY, 2001, 167 (01) :48-58
[8]  
Corti S., 2003, Current Gene Therapy, V3, P247, DOI 10.2174/1566523034578375
[9]   In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP [J].
Deng, WW ;
Obrocka, M ;
Fischer, I ;
Prockop, DJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 282 (01) :148-152
[10]   Treatment of neurodegenerative diseases using adult bone marrow stromal cell-derived neurons [J].
Dezawa, M ;
Hoshino, M ;
Ide, C .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (04) :427-435